Meeting
2020 Genitourinary Cancers Symposium
Serum microRNA-371a-3p levels to predict viable germ cell tumor in chemotherapy-naïve patients undergoing retroperitoneal lymph node dissection.
Authors
Nirmish Singla
University of Texas Southwestern Medical Center, Dallas, TX
Nirmish Singla , John T. Lafin , Solomon L. Woldu , Yair Lotan , Cheryl Lewis , Kuntal Majmudar , Anna Savalyeva , Alexander P. Kenigsberg , Payal Kapur , Vitaly Margulis , Douglas Strand , Matthew Murray , James F. Amatruda , Aditya Bagrodia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 417)
Abstract #
417
Poster Bd #
E16
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Predictive capacity of miRNA-375 in identifying teratoma in post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND).
First Author: Alexander P. Kenigsberg
Poster
2018 Genitourinary Cancers Symposium
Serum miRNA to predict post-chemotherapy viable disease in testicular non-seminomatous germ cell tumor patients.
First Author: Ricardo Romao Nazario Leao
Poster
2022 ASCO Genitourinary Cancers Symposium
Molecular analysis of primary testicular germ cell tumor and matched metastatic teratomas.
First Author: Anna Savelyeva
Poster
2022 ASCO Genitourinary Cancers Symposium
Viable germ cell tumor and teratoma can be distinguished from necrosis in postchemotherapy retroperitoneal lymph node dissection specimens by a combination of microRNA-371a-3p and 375-5p.
First Author: Tim Nestler